Inflammation and cardiac outcome

Current Opinion in Infectious Diseases

Volumn 24, Issue 3, 2011, Pages 259-264

  Hohensinner, Philipp J ^a,b   Niessner, Alexander ^a   Huber, Kurt ^c   Weyand, Cornelia M ^b   Wojta, Johann ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WILHELMINEN HOSPITAL   (Austria)

Author keywords

cardiovascular disease; cytokine; inflammation; macrophage; STAT

Indexed keywords

CHOLESTEROL; COLONY STIMULATING FACTOR 1; CYTOKINE; FRACTALKINE; GLYCOPROTEIN GP 130; GROWTH DIFFERENTIATION FACTOR 15; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; ONCOSTATIN M; STAT PROTEIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CYTOKINE PRODUCTION; HEART DISEASE; HEART FAILURE; HEART PROTECTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MACROPHAGE; MONOCYTE; NONHUMAN; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 85027928444     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328344f50f     Document Type: Article

References (53)

1. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol 2007; 147:227-235. (Pubitemid 46095999)
2. Kopf M, Bachmann MF, Marsland BJ. Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 2010; 9:703-718.
3. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5:e78.
4. Karakas M, Baumert J, Greven S, et al. Reproducibility in serial C-reactive protein and interleukin-6 measurements in postmyocardial infarction patients: results from the AIRGENE study. Clin Chem 2010; 56:861-864.
5. Patterson CC, Smith AE, Yarnell JW, et al. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study. Atherosclerosis 2010; 209:551-557.
6. Jug B, Salobir BG, Vene N, et al. Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure. Heart Vessels 2009; 24:271-276.
7. Empana JP, Jouven X, Canoui-Poitrine F, et al. C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: the PRIME study. Arterioscler Thromb Vasc Biol 2010; 30:2047-2052.
8. Fraser A, May M, Lowe G, et al. Interleukin-6 and incident coronary heart disease: results from the British Women?s Heart and Health Study. Atherosclerosis 2009; 202:567-572
9. Smith AJ, D?Aiuto F, Palmen J, et al. Association of serum interleukin-6 concentration with a functional IL6-6331TC polymorphism. Clin Chem 2008; 54:841-850. (Pubitemid 351671601)
10. Sie MP, Mattace-Raso FU, Uitterlinden AG, et al. The interleukin-6-174 G/C promoter polymorphism and arterial stiffness; the Rotterdam Study. Vasc Health Risk Manag 2008; 4:863-869.
11. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009; 20:43-59.
12. Weyand CM, Fujii H, Shao L, Goronzy JJ. Rejuvenating the immune system in rheumatoid arthritis. Nat Rev Rheumatol 2009; 5:583-588.
13. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009; 204:178-183.
14. Riikola A, Sipila K, Kahonen M, et al. Interleukin-6 promoter polymorphism and cardiovascular risk factors: the Health 2000 Survey. Atherosclerosis 2009; 207:466-470.
15. Rychli K, Kaun C, Hohensinner PJ, et al. The inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo. J Thromb Haemost 2010; 8:596-604.
16. Fischer P, Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol 2008 153 (Suppl 1):S414-S427. (Pubitemid 351341017)
17. Kurdi M,BoozGW.JAKredux: a second look at the regulation and role of JAKs in the heart. Am J Physiol Heart Circ Physiol 2009; 297:H1545-H1556.
18. Miyamoto S, Rubio M, Sussman MA. Nuclear and mitochondrial signalling Akts in cardiomyocytes. Cardiovasc Res 2009; 82:272-285.
19. Sussman M. ?AK'ing lessons for stem cells: regulation of cardiac myocyte and progenitor cell proliferation. Trends Cardiovasc Med 2007; 17:235-240. (Pubitemid 47532728)
20. Lorenz K, Schmitt JP, Vidal M, Lohse MJ. Cardiac hypertrophy: targeting Raf/ MEK/ERK1/2-signaling. Int J Biochem Cell Biol 2009; 41:2351-2355.
21. Jugdutt BI. Preventing adverse remodeling and rupture during healing after myocardial infarction in mice and humans. Circulation 2010; 122:103-105.
22. Hilfiker-Kleiner D, Shukla P, Klein G, et al. Continuous glycoprotein-130- mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 2010; 122:145-155.
23. Hohensinner PJ, Kaun C, Rychli K, et al. The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells. FASEB J 2009; 23:774-782.
24. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2010. [Epub ahead of print].
25. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371:987-997. (Pubitemid 351392039)
26. Heymans S, Hirsch E, Anker SD, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11:119-129.
27. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91:988-998. (Pubitemid 35416635)
28. Lacerda L, McCarthy J, Mungly SF, et al. TNFalpha protects cardiac mitochondria independently of its cell surface receptors. Basic Res Cardiol 2010; 105:751-762.
29. Burchfield JS, Dong JW, Sakata Y, et al. The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptor-associated factor 2 in the heart. Circ Heart Fail 2010; 3:157-164.
30. De Lemos JA, Morrow DA, Blazing MA, et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 2007; 50:2117-2124. (Pubitemid 350117348)
31. Hohensinner PJ, Rychli K, Zorn G, et al. Macrophage-modulating cytokines predict adverse outcome in heart failure. Thromb Haemost 2010; 103:435-441.
32. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation 2010; 121:2437-2445.
33. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327:656-661.
34. Tsujioka H, Imanishi T, Ikejima H, et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 2009; 54:130-138.
35. Liehn EA, Piccinini AM, Koenen RR, et al. A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J Am Coll Cardiol 2010; 56:1847-1857.
36. Panizzi P, Swirski FK, Figueiredo JL, et al. Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol 2010; 55:1629-1638.
37. White GE, Tan TC, John AE, et al. Fractalkine has antiapoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res 2010; 85: 825-835.
38. Husberg C, Nygard S, Finsen AV, et al. Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. J Mol Cell Cardiol 2008; 45:261-269.
39. Cappuzzello C, Napolitano M, Arcelli D, et al. Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients. Physiol Genomics 2009; 38:233-240.
40. Taddei S, Virdis A. Growth differentiation factor-15 and cardiovascular dysfunction and disease: malefactor or innocent bystander? Eur Heart J 2010; 31:1168-1171.
41. Will RD, Eden M, Just S, et al. Myomasp/LRRC39, a heart- and musclespecific protein, is a novel component of the sarcomeric M-band and is involved in stretch sensing. Circ Res 2010; 107:1253-1264.
42. Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 2010; 224:626-635.
43. Brown DA, Breit SN, Buring J, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 2002; 359:2159-2163. (Pubitemid 34694024)
44. Anand IS, Kempf T, Rector TS, et al. Serial measurement of growthdifferentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010; 122: 1387-1395.
45. Khan SQ, Ng K, Dhillon O, et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 2009; 30:1057-1065.
46. Bonaca MP, Morrow DA, Braunwald E, et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2010; 31:203-210.
47. Eggers KM, Kempf T, Lagerqvist B, et al. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-STsegment- elevation acute coronary syndrome. Circ Cardiovasc Genet 2010; 3:88-96.
48. Lind L, Wallentin L, Kempf T, et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 2009; 30:2346-2353.
49. Stahrenberg R, Edelmann F, Mende M, et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 2010; 12:1309-1316.
50. Schnabel RB, Schulz A, Messow CM, et al. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J 2010; 31:3024-3031.
51. Eggers KM, Kempf T, Allhoff T, et al. Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J 2008; 29:2327-2335.
52. Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006; 98:351-360.
53. Heger J, Schiegnitz E, von Waldthausen D, et al. Growth differentiation factor acts antiapoptotic and pro-hypertrophic in adult cardiomyocytes. J Cell Physiol 2010; 224:120-126.